Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Abiomed (NASDAQ: ABMD) is a leading provider of medical devices that provide circu...
Abiomed (NASDAQ: ABMD) is a leading provider of...
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming ...
Homology Medicines, Inc. is a genetic medicines...
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pi...
Applied Therapeutics is a clinical-stage biopha...
At Insmed we are on a mission to transform the lives of patients battling serious ...
At Insmed we are on a mission to transform the ...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...
Founded on September 28, 2005 through the merge...
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
Join the National Investor Network and get the latest information with your interests in mind.